CIO Middle East is proud to introduce the first CIO50 Middle East awards, recognising the top 50 senior technology executives driving innovation, strengthening resiliency, and influencing rapid change in the region.
Reflecting IDG s increasing commitment to the region, the CIO50 Middle East awards are aligned with a global awards programme and viewed as a mark of excellence within the enterprise.
The CIO50 Middle East awards this year were judged based on three core pillars innovation, leadership, and resiliency and honour transformational, inspiring, and enduring CIOs at both in-country and regional levels in the Middle East.
We received more than 80 submissions from the UAE, Saudi Arabia, Oman, Bahrain and Qatar in a record-breaking year for the awards programme. Winners were unveiled during a celebration ceremony hosted virtually and attended by more than 400 technology executives from across the region.
It looks like this was the result of either:
A mistyped address
A broken link on our site
A broken link on a search engine results page
A broken link on someone else s page
Some things to try:
Use the navigation menu at the top Most Read
January 29, 2021 2:45pm EST Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP). We are grateful to receive this funding from the DOD and for their demonstrated commitment towards finding safe and effective treatments for COVID-19 patients, said Raul Rodriguez, Rigel s president and CEO. These additional resources will contribute significantly to the advancement of our Phase 3 trial. D
Trump issues commendations to Operation Warp Speed members, including Fauci, Birx
By Catherine Park
Gen. Lloyd Austin says COVID-19 is the greatest threat America faces today
Addressing the Senate Armed Services Committee, Austin, who served 41 years in the Army, vowed to surround himself with qualified civilians and include them in policy decisions.
WASHINGTON - On his last day in office, President Donald Trump issued commendations to a number people for their contributions to Operation Warp Speed, a White House effort to distribute 300 million doses of a viable COVID-19 vaccine by January 2021, which by Jan. 19 had not been met.
A few names on the list of commendations stood out, particularly Dr. Anthony Fauci and Dr. Deborah Birx, both of whom were key members of the White House coronavirus task force in its early days, before having their public-facing roles diminished when the task force ceased providing regular briefings.